NTRC expands SynergyFinder™ platform with triple combination testing
NTRC’s SynergyFinder™ platform allows parallel in vitro screening of combinations and distinguishes additive from synergistic effects.
Read more
Prexton Therapeutics acquired by Lundbeck
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced March 16th the signing of a definitive agreement in which Lundbeck will acquire Prexton.
Read more
Ardena acquires ChemConnection adding API expertise
Contract development and manufacturing organisation (CDMO) Ardena has acquired ChemConnection.
Read more
InProcess-LSP ontvangt financiering voor nieuwe testtechniek ‘nanomedicijnen’
Life sciences-start-up InProcess-LSP haalt een investering op bij de Brabantse Ontwikkelings Maatschappij (BOM) voor de verdere ontwikkeling van de NanoFlowSizer.
Read more
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
Aduro Biotech announced that the company earned a $3.0 million development milestone payment under its worldwide licensing agreement with Merck for the initiation of a Phase I clinical trial of its anti-CD27 antibody.
Read more
Brigitte Drees nieuwe directeur Pivot Park
Brigitte Drees volgt Mirjam Mol-Arts op, welke 1 januari afscheid nam van het Pivot Park.
Read more
RA2day: addressing today’s regulatory topics
Zwiers Regulatory Consultancy is organising RA2day on April 13th 2018.
Read more
Over 50 companies based at Pivot Park!
Recently the number of companies based at Pivot Park reached the milestone of 50!
Read more
New at Pivot Park – PharmaCytics
PharmaCytics offers a drug delivery solution, based on an advanced prodrug approach.
Read more